Global Pet Vaccine Market - Industry Trends, Opportunities and Forecasts to 2023
The global pet vaccine market is projected to witness a CAGR of 7.10% during the forecast period to reach a total market size of US$4.402 billion by 2023, increasing from US$3.124 billion in 2018. Regular Vaccination is an important part of a responsible pet ownership. Maintaining the pet’s immunity to diseases plays an important part in community health in general. The growing adoption rate of pets and growing community awareness regarding pet health has been significantly driving the demand for the global pet vaccine market.
The share of pet vaccine market in North America has grown considerably. The region also possesses the highest pet ownership population which supplemented the growth of the market. The government initiatives creating the awareness regarding animal health has played a pivotal role in the growth of the market in the region.
The global pet vaccine market is segmented on the basis of animal type, vaccination, mode of administration, and geography. Based on animal type, the market is segmented into canine, feline, and others. Furthermore, the market is categorized on the basis of vaccination which includes canine family (core vaccines, non-core vaccines), feline family (core vaccines, non-core vaccines), and others.
The market is also segmented on the basis of mode of administration which includes injectable vaccines and intranasal vaccines. Further, the market is analyzed based on five regions, namely, North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The global pet vaccine market is a consolidated market with key players dominating the market. The market is highly profitable but requires adherence to strict government regulations. The report details strategies, products, and investments being done by key players in different technologies and companies to boost their market presence.
Some of the major players discussed in the report are Zoetis, Merck Sharp & Dohme Corp., Bayer AG, and Elanco US Inc. among others.
Segmentation
The global pet vaccine market has been segmented by animal types, by vaccination, by mode of administration, and by geography.
By Animals Type
Canine
Feline
Others
By Vaccination
Canine Family
Core Vaccines
Non-Core Vaccines
Feline Family
Core Vaccines
Non-Core Vaccines
Others
By mode of administration
Injectable Vaccines
Intranasal Vaccines
By Geography
North America
South America
Europe
Middle east and Africa
Asia Pacific
The share of pet vaccine market in North America has grown considerably. The region also possesses the highest pet ownership population which supplemented the growth of the market. The government initiatives creating the awareness regarding animal health has played a pivotal role in the growth of the market in the region.
The global pet vaccine market is segmented on the basis of animal type, vaccination, mode of administration, and geography. Based on animal type, the market is segmented into canine, feline, and others. Furthermore, the market is categorized on the basis of vaccination which includes canine family (core vaccines, non-core vaccines), feline family (core vaccines, non-core vaccines), and others.
The market is also segmented on the basis of mode of administration which includes injectable vaccines and intranasal vaccines. Further, the market is analyzed based on five regions, namely, North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The global pet vaccine market is a consolidated market with key players dominating the market. The market is highly profitable but requires adherence to strict government regulations. The report details strategies, products, and investments being done by key players in different technologies and companies to boost their market presence.
Some of the major players discussed in the report are Zoetis, Merck Sharp & Dohme Corp., Bayer AG, and Elanco US Inc. among others.
Segmentation
The global pet vaccine market has been segmented by animal types, by vaccination, by mode of administration, and by geography.
By Animals Type
Canine
Feline
Others
By Vaccination
Canine Family
Core Vaccines
Non-Core Vaccines
Feline Family
Core Vaccines
Non-Core Vaccines
Others
By mode of administration
Injectable Vaccines
Intranasal Vaccines
By Geography
North America
South America
Europe
Middle east and Africa
Asia Pacific
1. INTRODUCTION
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Prevalence
4.6. Industry Regulations
4.7. Product Pipeline
4.8. Innovations
4.9. Scenario Analysis
5. GLOBAL PET VACCINE MARKET FORECAST BY ANIMAL TYPE (US$ BILLION)
5.1. Introduction
5.2. Canine
5.3. Feline
5.4. Others
6. GLOBAL PET VACCINE MARKET FORECAST BY VACCINATION (US$ BILLION)
6.1. Introduction
6.2. Canine Family
6.2.1. Core Vaccines
6.2.2. Non-Core Vaccines
6.3. Feline Family
6.3.1. Core Vaccines
6.3.2. Non-Core Vaccines
6.4. Others
7. GLOBAL PET VACCINE MARKET FORECAST BY MODE OF ADMINISTRATION (US$ BILLION)
7.1. Introduction
7.2. Injectable Vaccines
7.3. Intranasal Vaccines
8. GLOBAL PET VACCINE FORECAST BY GEOGRAPHY (US$ BILLION)
8.1. Introduction
8.2. North America
8.3. South America
8.4. Europe
8.5. Middle East and Africa
8.6. Asia Pacific
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments And Deals
10. COMPANY PROFILES
10.1. Bayer AG
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Key Developments
10.2. Elanco US Inc.
10.2.1. Overview
10.2.2. Financials
10.2.3. Products and Services
10.2.4. Key Developments
10.3. Merck Sharp & Dohme Corp
10.3.1. Overview
10.3.2. Financials
10.3.3. Products and Services
10.3.4. Key Developments
10.4. Merial Inc.
10.4.1. Overview
10.4.2. Financials
10.4.3. Products and Services
10.4.4. Key Developments
10.5. Virbac
10.5.1. Overview
10.5.2. Financials
10.5.3. Products and Services
10.5.4. Key Developments
10.6. Zoetis
10.6.1. Overview
10.6.2. Financials
10.6.3. Products and Services
10.6.4. Key Developments
10.7. Phibro Animal Health Corporation
10.7.1. Overview
10.7.2. Financials
10.7.3. Products and Services
10.7.4. Key Developments
10.8. Boehringer Ingelheim GmbH
10.8.1. Overview
10.8.2. Financials
10.8.3. Products and Services
10.8.4. Key Developments
10.9. Tianjin Ringpu Bio-Technology Co., Ltd
10.9.1. Overview
10.9.2. Financials
10.9.3. Products and Services
10.9.4. Key Developments
10.10. Vetoquinol
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Key Developments
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Prevalence
4.6. Industry Regulations
4.7. Product Pipeline
4.8. Innovations
4.9. Scenario Analysis
5. GLOBAL PET VACCINE MARKET FORECAST BY ANIMAL TYPE (US$ BILLION)
5.1. Introduction
5.2. Canine
5.3. Feline
5.4. Others
6. GLOBAL PET VACCINE MARKET FORECAST BY VACCINATION (US$ BILLION)
6.1. Introduction
6.2. Canine Family
6.2.1. Core Vaccines
6.2.2. Non-Core Vaccines
6.3. Feline Family
6.3.1. Core Vaccines
6.3.2. Non-Core Vaccines
6.4. Others
7. GLOBAL PET VACCINE MARKET FORECAST BY MODE OF ADMINISTRATION (US$ BILLION)
7.1. Introduction
7.2. Injectable Vaccines
7.3. Intranasal Vaccines
8. GLOBAL PET VACCINE FORECAST BY GEOGRAPHY (US$ BILLION)
8.1. Introduction
8.2. North America
8.3. South America
8.4. Europe
8.5. Middle East and Africa
8.6. Asia Pacific
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments And Deals
10. COMPANY PROFILES
10.1. Bayer AG
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Key Developments
10.2. Elanco US Inc.
10.2.1. Overview
10.2.2. Financials
10.2.3. Products and Services
10.2.4. Key Developments
10.3. Merck Sharp & Dohme Corp
10.3.1. Overview
10.3.2. Financials
10.3.3. Products and Services
10.3.4. Key Developments
10.4. Merial Inc.
10.4.1. Overview
10.4.2. Financials
10.4.3. Products and Services
10.4.4. Key Developments
10.5. Virbac
10.5.1. Overview
10.5.2. Financials
10.5.3. Products and Services
10.5.4. Key Developments
10.6. Zoetis
10.6.1. Overview
10.6.2. Financials
10.6.3. Products and Services
10.6.4. Key Developments
10.7. Phibro Animal Health Corporation
10.7.1. Overview
10.7.2. Financials
10.7.3. Products and Services
10.7.4. Key Developments
10.8. Boehringer Ingelheim GmbH
10.8.1. Overview
10.8.2. Financials
10.8.3. Products and Services
10.8.4. Key Developments
10.9. Tianjin Ringpu Bio-Technology Co., Ltd
10.9.1. Overview
10.9.2. Financials
10.9.3. Products and Services
10.9.4. Key Developments
10.10. Vetoquinol
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Key Developments
